Document is current
Any future updates will be listed below
-
Authors
Xu, Mengyao
Barakzai, Syem K.
Kumar, Raj
Veillard, Irva
Kim, Eugene
Bregar, Amy
Eisenhauer, Eric
Penson, Richard
Bouberhan, Sara
Filipi, Jennifer
Colella, Tina
Bond, Tim
Clark, Caroline
Lin, Lawrence H.
Ruan, Jinpeng
Wang, Cheng https://orcid.org/0000-0002-0911-8254
Qin, Xingping https://orcid.org/0000-0003-3263-0843
Sarosiek, Kristopher https://orcid.org/0000-0002-4618-5085
Rueda, Bo
Castro, Cesar https://orcid.org/0000-0002-1159-5658
Spriggs, David R.
Yeku, Oladapo O. https://orcid.org/0000-0002-6319-1647
-
Funding
Funding for this research was provided by:
Nile Albright Research Foundation, The Flatley Foundation, The Worden Family Foundation, The Barshad Family.
Vincent Memorial Hospital Foundation
- License Information
-
More Information
Article History
Received: 16 March 2025
Revised: 21 October 2025
Accepted: 11 November 2025
First Online: 19 December 2025
Competing interests
: O.O.Y. reports grants from Ascendis Pharma A/S, Immunocore Limited, Duality Biologics, Merck Sharp & Dohme Corporation, ProfoundBio, and the Department of Defense. Consulting fees from Aadi Bioscience. Advisory board role at hC Bioscience. In addition, he has a patent pending for MUC16 Directed Antibodies for therapeutic applications, and a patent pending for Human Artificial Chromosomes for therapeutic applications. D.R.S. is a co-inventor of the MUC16ecto antibody 4H11 and the patent is held jointly by Memorial Sloan Kettering Cancer Center and Eureka Therapeutics. A patent application has been filed for the modified human 4H11 antibody. The remaining authors declare no competing interests.
: All patients were consented to the Mass General Brigham Institutional Review Board approved biobanking protocol 07-049 and all experiments were performed under the Mass General Brigham Institutional Review Board approved Excess Human Material secondary use protocol 2019P003362. All experiments were performed in accordance with relevant guidelines and regulations.
